Updates are available Correction dated 2020-01-02

Article History

Received: 26 March 2019

Accepted: 24 November 2019

First Online: 5 December 2019

Change Date: 2 January 2020

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00787-019-01465-8

Compliance with ethical standards

:

: Barbara Alm was involved in Phase-III studies for Medice, Eli Lilly, and Novartis; was on Eli Lilly’s advisory board; and received speakers’ fees from Medice. Katja Becker received speakers´ fees (independent lecture content) from Shire during the last 3 years (Dec 2015). No research/clinical trials sponsored by pharmaceutical industry within the last 5 years and no advisory boards within the last 4 years. She is involved in clinical trials funded by the German Federal Ministry of Education and Research (ESCAlife, ProHEAD). Michael Colla was on advisory boards, received speakers’ honoraria, and participated in Phase-III studies for Shire, Eli Lilly, and Novartis within the last 3 years. Christine M. Freitag was an independent consultant for Desitin and Roche during the last 3 years. She receives royalties for books on ADHD, Autism Spectrum Disorder and Major Depressive Disorder. She receives research funding from the German Research Foundation DFG and the European Commission. Alexander Häge received speakers´ fees, was on advisory boards or has been involved in clinical trials by Shire, Janssen-Cilag, Otsuka, Lundbeck, Servier and Nuvelution. Sarah Hohmann received speakers’ fees from Jansen Cilag in 2012. Martin Holtmann served in an advisory role for Shire and Medice, and received conference attendance support or was paid for public speaking by Lilly, Medice, Neuroconn, and Shire. He receives research support from the German Research Foundation and the German Ministry of Education and Research. He receives royalties as Editor in Chief of the German Journal for Child and Adolescent Psychiatry and for textbooks from Hogrefe. Christian Jacob received speakers’ fees from Novartis and Medice and is a member of the adult ADHD Advisory Board of the latter company. Swantje Matthies received speakers’ fees from Janssen-Cilag and was involved in clinical trials conducted by Janssen-Cilag and Lilly. Alexandra Philipsen was on advisory boards, presented lectures, was involved in Phase-III studies, and received travel grants from Eli Lilly, Janssen-Cilag, Medice, Novartis, and Shire within the last 3 years; she is the author of books and articles on psychotherapy published by Elsevier, Hogrefe, Schattauer, Kohlhammer, and Karger; she is involved in clinical trials funded by the German Federal Ministry of Education and Research. Luise Poustka received speakers’ fees from Eli Lilly and Shire and was an independent consultant for Roche during the last 3 years. She receives royalties for books and book chapters on Autism Spectrum Disorder by Hogrefe and Schattauer and research funding from the German Federal Ministry of Education and Research and the European Commission. Wolfgang Retz received speakers’ fees from and is on advisory boards of Medice, Novartis, and Shire; he is involved in clinical trials for the German Ministry of Education and Research (BMBF), Novartis, Medice, and Vifor. A. von Gontard was invited by Eli Lilly to present two lectures. Michael Rösler is a member of the Medice, Janssen, and Shire speakers’ bureaus; is a member of Lilly, Shire, Medice, and Janssen advisory boards; and performed clinical trials for Medice and Lilly. Esther Sobanski was on advisory boards, was involved in Phase-III studies or investigator-initiated trials, and presented lectures for Medice, Shire, Eli Lilly, and Novartis within the last 3 years. Alexander von Gontard was invited by Eli Lilly to present two lectures. Andreas Warnke received speakers’ fees from Janssen-Cilag, Medice, Novartis, and Lilly and was involved in clinical trials conducted by Lilly, Novartis, Medice, and Shire; no fees or research funding have been awarded in the last 2 years. Klaus Hennighausen died before the manuscript could be finalized. He did not report any conflicts of interest with respect to other articles on the AIMAC study. All other authors (Barbara Haack-Dees, Laura Gentschow, Erika Graf, Julia M. Geissler, Susann Hänig, Charlotte Jaite, Thomas Jans, Viola Kappel, Timo D. Vloet, Katja Schneider-Momm and Nora Strom) declare no conflicts of interest.

: The study received appropriate ethics committee approval from the leading Ethics Committee (Faculty of Medicine, Wuerzburg University, 120/06) and the local ethics committees and was authorised by the competent German authorities. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All participants gave their informed consent and assent prior to their inclusion in the study.